By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



99 Hayden Avenue
Suite 390
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-357-2333 Fax: 781-357-2399



Company News
Pulmatrix Initiates European Pilot Bioequivalence Study Of PUR0200 For COPD 2/1/2016 6:50:18 AM
Pulmatrix To Present At Upcoming Investor Conferences 1/7/2016 10:47:46 AM
Pulmatrix To List On Nasdaq Global Market 12/18/2015 6:31:28 AM
Pulmatrix Reports 3rd Quarter Results; Provides Update On Business & Development Pipeline 11/12/2015 10:15:12 AM
Pulmatrix To Webcast Investor Presentation At Upcoming Investor Conferences 10/9/2015 7:52:50 AM
Study: Pulmatrix's PUR1900 Inhaled Cystic Fibrosis Drug Demonstrates High Lung Retention And Potency Against Fungal Infection 10/8/2015 6:24:56 AM
NIH Awards $1.7 Million Grant For Celdara Medical And Pulmatrix To Develop An Inhaled Biologic Treatment For Idiopathic Pulmonary Fibrosis 10/1/2015 6:34:52 AM
Pulmatrix To Report Clinical Data On PUR0200 In Patients With Chronic Obstructive Pulmonary Disease 9/24/2015 12:04:12 PM
Pulmatrix To Highlight PUR1900 Data At 2015 North American Cystic Fibrosis Conference 9/11/2015 9:05:49 AM
Pulmatrix To Present At The Rodman & Renshaw Global Investment Conference On September 10, 2015 9/3/2015 7:01:05 AM